Shanafelt Armen

CIK 00016561514 companiesINDIANAPOLIS, IN

SEC Profile

Transactions

Companies

Filings

CIK

0001656151

Recent Transactions

38 trades

Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2022-06-08+24,000→ 24,000 total
Award
Spyre Therapeutics, Inc.$SYRE
Director Stock Option (right to buy)
2022-06-07+43,000→ 43,000 total
Purchase
Spyre Therapeutics, Inc.$SYRE
Common Stock
2021-12-13$3.65/sh+14,685→ 150,000 total
Purchase
Spyre Therapeutics, Inc.$SYRE
Common Stock
2021-12-10$3.65/sh+13,516→ 135,315 total
Purchase
Spyre Therapeutics, Inc.$SYRE
Common Stock
2021-12-09$3.67/sh+121,799→ 121,799 total
Award
Spyre Therapeutics, Inc.$SYRE
Director Stock Option (right to buy)
2021-06-08+40,000→ 40,000 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2021-06-08+17,700→ 17,700 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2020-06-10+12,000→ 12,000 total
Award
Spyre Therapeutics, Inc.$SYRE
Director Stock Option (right to buy)
2020-06-08+28,100→ 28,100 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2019-10-01+16,531→ 16,531 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2019-07-01+6,937→ 6,937 total
Award
Spyre Therapeutics, Inc.$SYRE
Director Stock Option (right to buy)
2019-06-07+12,400→ 12,400 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2019-06-05+12,100→ 12,100 total
Award
Rein Therapeutics, Inc.$RNTX
Stock Option (right to buy)
2018-06-21+10,000→ 10,000 total
Award
Spyre Therapeutics, Inc.$SYRE
Director Stock Option (right to buy)
2018-06-07+18,400→ 18,400 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2018-05-29+12,000→ 12,000 total
Conversion
Surface Oncology, Inc.
Series A Preferred Stock
2018-04-23−7,000,000→ 0 total
Purchase
Surface Oncology, Inc.
Common Stock
2018-04-23$15.00/sh+266,000→ 3,447,817 total
Conversion
Surface Oncology, Inc.
Common Stock
2018-04-23+3,181,817→ 3,181,817 total
Award
Spyre Therapeutics, Inc.$SYRE
Director Stock Option (right to buy)
2017-12-01+30,000→ 30,000 total
Award
Rein Therapeutics, Inc.$RNTX
Stock Option (right to buy)
2017-07-25+20,000→ 20,000 total
Conversion
Rein Therapeutics, Inc.$RNTX
Common Stock
2017-07-05+844,987→ 844,987 total
Purchase
Rein Therapeutics, Inc.$RNTX
Common Stock
2017-07-05$15.00/sh+250,000→ 1,094,987 total
Conversion
Rein Therapeutics, Inc.$RNTX
Series E-2 Preferred Stock
2017-07-05−1,907,373→ 0 total
Conversion
Rein Therapeutics, Inc.$RNTX
Series E-3 Preferred Stock
2017-07-05−1,654,411→ 0 total
Conversion
Rein Therapeutics, Inc.$RNTX
Series F Preferred Stock
2017-07-05−1,443,972→ 0 total
Conversion
Rein Therapeutics, Inc.$RNTX
Series D Preferred Stock
2017-07-05−3,390,885→ 0 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2017-05-25+12,000→ 12,000 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2016-09-13+24,000→ 24,000 total
Purchase
Protagonist Therapeutics, Inc$PTGX
Common Stock
2016-08-16$12.00/sh+583,333→ 2,099,482 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Series B Preferred Stock
2016-08-16−9,142,857→ 0 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2016-08-16+206,896→ 206,896 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2016-08-16+678,712→ 1,516,149 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Series A Preferred Stock
2016-08-16−3,000,000→ 0 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Series C Preferred Stock
2016-08-16−9,841,333→ 0 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2016-08-16+630,541→ 837,437 total
Award
Spyre Therapeutics, Inc.$SYRE
Director Stock Option (right to buy)
2016-05-17+24,000→ 24,000 total
Conversion
Spyre Therapeutics, Inc.$SYRE
Common Stock
2016-04-12+2,010,924→ 2,068,543 total

Shanafelt Armen

Recent Transactions

Companies

Recent Filings

Address